Epidemiology & Risk Factors

  • Demographics: Adults aged 30–50; fair-skinned individuals (Fitzpatrick skin types I–II; Northern European descent); females > males (males present with more severe phymatous changes).
  • Triggers:
    • Temperature extremes, hot beverages, heat exposure.
    • Alcohol, spicy foods.
    • Sun/UV light exposure, physical exertion, emotional stress.
  • Pathogenesis: Neurovascular dysregulation + immune dysregulation + proliferation of cutaneous commensals (e.g., Demodex folliculorum mites).

Clinical Features

  • Erythematotelangiectatic Rosacea:
    • Central facial flushing and persistent erythema.
    • Telangiectasias (cheeks, nose, forehead).
    • Sensations of burning, stinging, or skin sensitivity.
  • Papulopustular Rosacea:
    • Central facial inflammatory papules and pustules.
    • Absence of comedones (critical clinical distinction from acne vulgaris).
  • Phymatous Rosacea:
    • Hypertrophy of sebaceous glands and fibrous tissue.
    • Rhinophyma (bulbous enlargement and irregular surface of the nose; almost exclusively in men).
  • Ocular Rosacea (up to 50% of pts; can precede cutaneous signs):
    • Foreign-body / “gritty” sensation, burning, stinging, photophobia.
    • Blepharitis, conjunctival injection, chalazion/hordeolum recurrence.
    • Potential for keratitis and corneal ulceration.

Diagnosis

  • Initial/Screening: Clinical diagnosis based on characteristic morphology, central facial distribution, and episodic flushing triggered by specific factors.
  • Confirmatory/Gold Standard: Clinical evaluation. Diagnostic testing generally unnecessary.
  • Key Labs: None indicated routinely. Antinuclear antibody (ANA) only if ruling out systemic lupus erythematosus (SLE).
  • Imaging: Not indicated.
  • Biopsy: Rarely indicated; reserved for atypical presentations to exclude cutaneous lupus, granulomatous disease (sarcoidosis), or demodicosis.

Differential Diagnostics

  • Acne Vulgaris:
    • Diff by presence of comedones (open/closed); involves extrafacial sites (back, chest, shoulders); typically younger age of onset (adolescence).
  • Systemic Lupus Erythematosus (Malar Rash):
    • Diff by sparing of nasolabial folds, absence of pustules/papules, systemic features (fever, arthritis, serositis, nephritis), and (+) ANA/anti-dsDNA.
  • Seborrheic Dermatitis:
    • Diff by greasy, yellowish scale predominantly over nasolabial folds, eyebrows, and scalp; absence of flushing or pustules.
  • Perioral Dermatitis:
    • Diff by papules/pustules confined to the perioral area with a distinct rim of sparing around the vermilion border; often precipitated by topical corticosteroid abuse.
  • Carcinoid Syndrome:
    • Diff by episodic flushing associated with systemic signs: secretory diarrhea, wheezing, and tricuspid regurgitation murmurs; (+) elevated 24-hr 5-HIAA.

Management

  • General Measures (All Subtypes):
    • Trigger avoidance: Sun protection (broad-spectrum SPF ≥ 30 daily), avoid alcohol, hot beverages, and spicy foods.
    • Gentle skin care: Mild soap-free cleansers, avoidance of abrasive scrubs or astringents.
  • Erythematotelangiectatic (Flushing & Telangiectasias):
    • First-line (Transient erythema): Topical vasoconstrictors (e.g., brimonidine [alpha-2 agonist], oxymetazoline).
    • First-line (Persistent telangiectasias): Laser therapy (pulsed-dye laser [PDL]) or intense pulsed light (IPL).
  • Papulopustular Rosacea:
    • First-line (Mild–Moderate): Topical metronidazole, topical azelaic acid, or topical ivermectin.
    • Second-line (Moderate–Severe / Refractory to topical therapy): Oral tetracyclines (e.g., low-dose or anti-inflammatory doxycycline, minocycline).
    • Refractory / Severe: Oral isotretinoin.
  • Ocular Rosacea:
    • Mild: Eyelid hygiene, warm compresses, artificial tears.
    • Moderate–Severe: Oral tetracyclines (e.g., doxycycline) or ophthalmic topical cyclosporine.
  • Phymatous Rosacea:
    • Early / Inflammatory: Oral isotretinoin.
    • Advanced / Fibrotic (Rhinophyma): Surgical debulking, electrosurgery, or ablative carbon dioxide laser resurfacing.

Complications

  • Vision-threatening ocular disease: Severe blepharitis, episcleritis, keratitis, corneal scarring, corneal perforation.
  • Permanent facial disfigurement: Progressive irreversible soft-tissue and sebaceous hypertrophy (rhinophyma).
  • Psychosocial morbidity: High rates of anxiety, depression, and social avoidance.